

10. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of <sup>68</sup>Ga-DOTATOC PET and <sup>111</sup>In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2007;34:1617–1626.
11. Gayana S, Mittal BR, Bhattacharya A, et al. <sup>68</sup>Ga-DOTATATE PET/CT imaging in carotid body tumor. *Clin Nucl Med*. 2013;38:e191–e193.
12. Kabasakal L, Demirci E, Ocak M, et al. Comparison of <sup>68</sup>Ga-DOTATATE and <sup>68</sup>Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2012;39:1271–1277.
13. Klinaki I, Al-Nahhas A, Soneji N, et al. <sup>68</sup>Ga DOTATATE PET/CT uptake in spinal lesions and MRI correlation on a patient with neuroendocrine tumor: potential pitfalls. *Clin Nucl Med*. 2013;38:e449–e453.
14. Lapa C, Lohr M, Bluemel C, et al. Primary central nervous system lymphoma and meningioma in DOTATATE PET/CT. *Clin Nucl Med*. 2013;38:994–995.
15. Zhao X, Xiao JQ, Xing B, et al. Comparison of <sup>68</sup>Ga-DOTATATE to <sup>18</sup>F-FDG uptake is useful in the differentiation of residual or recurrent pituitary adenoma from the remaining pituitary tissue after transsphenoidal adenectomy. *Clin Nucl Med*. 2014;39:605–608.
16. Sahdev A, Reznick RH, Evanson J, et al. Imaging in Cushing's syndrome. *Arq Bras Endocrinol Metabol*. 2007;51:1319–1328.
17. Testa RM, Albiger N, Occhi G, et al. The usefulness of combined biochemical tests in the diagnosis of Cushing's disease with negative pituitary magnetic resonance imaging. *Eur J Endocrinol*. 2007;156:241–248.
18. Salenave S, Gatta B, Pecheur S, et al. Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropic-secreting microadenomas. *J Clin Endocrinol Metab*. 2004;89:3371–3376.
19. Bartynski WS, Lin L. Dynamic and conventional spin-echo MR of pituitary microlesions. *AJNR Am J Neuroradiol*. 1997;18:965–972.
20. Tabarin A, Laurent F, Catargi B, et al. Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. *Clin Endocrinol (Oxf)*. 1998;49:293–300.
21. Bergström M, Muhr C, Lundberg PO. PET as a tool in the clinical evaluation of pituitary adenomas. *J Nucl Med*. 1991;32:610–615.
22. Chittiboina P, Montgomery BK, Millo C, et al. High-resolution <sup>18</sup>F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. *J Neurosurg*. 2015;122:791–797.

### Erratum

In the Newsline article “Report Targets Acceleration of Cancer Research to Meet Moonshot Goals” (*J Nucl Med*. 2018;59:14N), Dr. Sanjiv Sam Gambhir was inadvertently left out of the list of collaborators. The list of collaborators should read “A number of SNMMI members served as commissioners and contributed to development of the report. They include SNMMI immediate-past-president Sally Schwarz, MS, RPh, BCNP; SNMMI past-president Hossein Jadvar, MD, PhD, MPH, MBA; David Mankoff, MD, PhD; Martin G. Pomper, MD, PhD; Richard Wahl, MD; and Sanjiv Sam Gambhir, MD, PhD.” We regret the error.